Sanofi, Bristol Discussing Changes To Avapro Agreement
This article was originally published in The Pink Sheet Daily
Executive Summary
Sanofi and Bristol-Myers Squibb are likely to make changes to the co-promotion for the antihypertensive Avapro, Sanofi said during an Aug. 31 analysts conference call
You may also be interested in...
Size Of Bristol's Sales Force Not An Issue In Sanofi Copromotion Deal, Exec Says
Bristol-Myers Squibb's discussions with Sanofi-Aventis regarding Plavix and Avapro copromotion will focus on business needs, not relative sales force sizes, Bristol said
Size Of Bristol's Sales Force Not An Issue In Sanofi Copromotion Deal, Exec Says
Bristol-Myers Squibb's discussions with Sanofi-Aventis regarding Plavix and Avapro copromotion will focus on business needs, not relative sales force sizes, Bristol said
Sanofi-Aventis Merger Complete
Sanofi-Aventis launches as the third largest pharmaceutical company in the world following completion of the Sanofi-Synthelabo/Aventis merger